<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550249</url>
  </required_header>
  <id_info>
    <org_study_id>Neo-nivo</org_study_id>
    <nct_id>NCT02550249</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Nivolumab in Glioblastoma</brief_title>
  <acronym>Neo-nivo</acronym>
  <official_title>Phase II Study of Neoadjuvant Nivolumab in Patients With Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neoadjuvant nivolumab will be administered to patients with primary and recurrent&#xD;
      glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neoadjuvant nivolumab will be administered to patients with primary and recurrent&#xD;
      glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery&#xD;
      until toxicity or progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in percentage and level of expression of Programmed Death-Ligand 1 (PD-L1) by tumor cells and lymphocytes, assessed at baseline and following neoadjuvant nivolumab in Glioblastoma multiforme (GBM).</measure>
    <time_frame>1 neoadjuvant cycle followed by surgery (4 weeks). Evaluation will be performed at baseline and after the neoadjuvant cycle</time_frame>
    <description>We will assess levels of expression of Programmed Death-Ligand 1 (PD-L1) by tumor cells and lymphocytes at baseline and following neoadjuvant nivolumab in Glioblastoma multiforme (GBM). The specific outcome will be the changes in these levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: response rate assessed by Response Assessment in Neuro-Oncology (RANO) criteria</measure>
    <time_frame>1 neoadjuvant cycle followed by surgery (4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: toxicity assessed by Common Toxicity Criteria (CTC) version 4</measure>
    <time_frame>1 neoadjuvant cycle followed by surgery (4 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 3 mg every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Intravenous administration of nivolumab</description>
    <arm_group_label>Nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Patients must be willing and able to comply with scheduled visits, treatment schedule,&#xD;
             laboratory testing and other requirements of the study.&#xD;
&#xD;
          -  Patients with GBM that are candidates to primary or salvage resection surgery,&#xD;
             according to the following criteria:&#xD;
&#xD;
          -  Patients may have received previous treatments for GBM. There is no limit on previous&#xD;
             treatment lines, as long as the other inclusion criteria are met.&#xD;
&#xD;
          -  Patients in whom surgery can be safely delayed for a minimum period of 2 weeks&#xD;
             following the administration of the first dose of nivolumab, in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Eastern Cancer Oncology Group (ECOG) performance status of 0-1. Patients with ECOG&gt;1&#xD;
             due to neurological symptoms considered to be reversible following surgery, according&#xD;
             to investigator´s criteria will be eligible&#xD;
&#xD;
          -  Life expectancy &gt;12 weeks.&#xD;
&#xD;
          -  Adequate organ function defined by:&#xD;
&#xD;
               1. Bone Marrow Reserve: white blood cells (WBC): ≥2000/ mm3 absolute neutrophil&#xD;
                  count (ANC) ≥1500x 109/L; platelet count ≥100000/ mm3 100 x 109/L; hemoglobin&#xD;
                  ≥9.0 g/dL).&#xD;
&#xD;
               2. Hepatic: bilirubin &lt;1.5 times the upper limit of normality (ULN), AST and ALT&#xD;
                  &lt;3.0 × ULN (BR&lt; 3 x ULN for patients with Gilbert´s Syndrome).&#xD;
&#xD;
               3. Renal: creatinine &lt; 1.5 x ULN or estimated creatinine clearance &gt; 40 ml/min,&#xD;
                  using the Cockcroft-Gault formula.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of extracranial disease.&#xD;
&#xD;
          -  Any serious or uncontrolled medical disorder that, in the opinion of the investigator,&#xD;
             may increase the risk associated with study participation or study drug&#xD;
             administration, impair the ability of the subject to receive the planned therapy&#xD;
             (including brain surgery), or interfere with the interpretation of study results.&#xD;
&#xD;
          -  Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo,&#xD;
             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only&#xD;
             requiring hormone replacement, psoriasis not requiring systemic treatment, or&#xD;
             conditions not expected to recur in the absence of an external trigger are permitted&#xD;
             to enroll.&#xD;
&#xD;
          -  Previous treatment with a PD-1, PDL1 or CTLA-4 targeted therapy&#xD;
&#xD;
          -  Treatment with any anti-cancer drug or radiation therapy within the last 14 days. A&#xD;
             shorter interval can be approved by the principal investigator, if deemed appropriate.&#xD;
&#xD;
          -  Patients should be excluded if they have a condition requiring systemic treatment with&#xD;
             either corticosteroids (&gt;10 mg daily prednisone equivalents), with the exception of&#xD;
             control of cerebral edema, or other immunosuppressive medications within 14 days of&#xD;
             study drug administration. Inhaled or topical steroids and adrenal replacement doses &gt;&#xD;
             10 mg daily prednisone equivalents are permitted in the absence of active autoimmune&#xD;
             disease.&#xD;
&#xD;
          -  Pregnant or breastfeeding patients.&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (AIDS). Routine testing is not required.&#xD;
&#xD;
          -  Positive tests for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus&#xD;
             ribonucleic acid (HCV RNA) indicating active or chronic infection.&#xD;
&#xD;
          -  History of allergy to study drug components or of severe hypersensitivity reactions to&#xD;
             any monoclonal antibodies.&#xD;
&#xD;
          -  Prisoners or subjects who are involuntarily incarcerated or who are compulsorily&#xD;
             detained for treatment of either a psychiatric or physical (eg, infectious disease)&#xD;
             illness.&#xD;
&#xD;
          -  Subjects unable (due to existent medical condition, e.g, pacemaker or implantable&#xD;
             cardioverter defibrillator device) or unwilling to have a head contrast enhanced MRI&#xD;
             and/or a CT scan of the brain.&#xD;
&#xD;
          -  Concomitant or prior malignancy that, in the opinion of the investigator&#xD;
             contraindicates GBM surgery or can interfere with the results of the study, in the&#xD;
             opinion of the investigator.&#xD;
&#xD;
          -  Known drug or alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignacio Melero, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

